Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 3/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510938 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19584783 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23144727 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL144878 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL37778 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL675417 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL17776486 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL12646116 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23699767 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19156379 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230085402-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-16 | — | — | US | claimed |
| EP-4097487-A1 | BIOMARKERS | Oxford University Innovation Limited (GB) | 2022-12-07 | — | — | EP | claimed |
| WO-2021152330-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-08-05 | — | — | WO | claimed |
| EP-2396658-B1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | UNIV BIRMINGHAM (GB) | 2015-12-16 | — | — | EP | claimed |
| EP-0269786-B1 | Quantitative analysis of 3-oxo-5Beta-Steroid and reagent therefor | DAIICHI PURE CHEMICALS CO LTD (JP) | 1993-11-03 | — | — | EP | claimed |
| US-5085989-A | Contacting sample with specific dehydrogenase and tetrazolium salt, measuring optical density of colored substance produced; diagnosis of liver disorders | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1992-02-04 | — | — | US | claimed |
| CN-119950517-A | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114828889-B | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-02-14 | — | — | CN | disclosed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230085402-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-5085989-A | Contacting sample with specific dehydrogenase and tetrazolium salt, measuring optical density of colored substance produced; diagnosis of liver disorders | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| US-5028600-A | Oil in Water Emulsion of Pregnanolone | KABIVITRUM AB (SE) | 1991-07-02 | — | — | US | disclosed |
| EP-0233849-B1 | COMPOSITION OF PREGNANOLOLE COMPRISING A STABLE OIL-IN-WATER EMULSION | Kabi Pharmacia AB (SE) | 1991-06-19 | — | — | EP | disclosed |
| EP-0269786-A1 | Quantitative analysis of 3-oxo-5Beta-Steroid and reagent therefor | DAIICHI PURE CHEMICALS CO. LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| EP-0233849-A1 | Composition of pregnanolole comprising a stable oil-in-water emulsion | Kabi Pharmacia AB (SE) | 1987-08-26 | — | — | EP | disclosed |
| US-4397947-A | NOCARDIA | G. D. SEARLE & CO. (US) | 1983-08-09 | — | — | US | disclosed |
| US-4034749-A | Intrauterine contraceptive device | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | AKR1B10 298/4885AKR1B1 189/4885GPBAR1 241/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | AKR1B10 298/4885AKR1B1 189/4885GPBAR1 241/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | AKR1B10 298/4885AKR1B1 189/4885GPBAR1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.